Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Leases (2019 - 2025)

Historic Current Leases for RedHill Biopharma (RDHL) over the last 7 years, with Q2 2025 value amounting to $214000.0.

  • RedHill Biopharma's Current Leases fell 4184.78% to $214000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $214000.0, marking a year-over-year decrease of 4184.78%. This contributed to the annual value of $353000.0 for FY2024, which is 5083.57% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Current Leases is $214000.0, which was down 4184.78% from $353000.0 recorded in Q4 2024.
  • RedHill Biopharma's 5-year Current Leases high stood at $7.2 million for Q1 2022, and its period low was $214000.0 during Q2 2025.
  • Moreover, its 5-year median value for Current Leases was $2.9 million (2021), whereas its average is $3.4 million.
  • As far as peak fluctuations go, RedHill Biopharma's Current Leases skyrocketed by 15031.08% in 2022, and later tumbled by 8885.61% in 2023.
  • Over the past 5 years, RedHill Biopharma's Current Leases (Quarter) stood at $2.6 million in 2021, then skyrocketed by 150.31% to $6.4 million in 2022, then crashed by 88.86% to $718000.0 in 2023, then tumbled by 50.84% to $353000.0 in 2024, then crashed by 39.38% to $214000.0 in 2025.
  • Its Current Leases stands at $214000.0 for Q2 2025, versus $353000.0 for Q4 2024 and $368000.0 for Q2 2024.